
Positive Phase 2 Alzheimer’s Study Data Published, Met Primary and Secondary Endpoints
Positive Phase 2 Alzheimer’s Study Data Published, Met Primary and Secondary Endpoints Sinaptica Therapeutics, Inc., a clinical-stage company pioneering personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the publication of positive results from its 52-week Phase 2…












